Table 3.
Patient outcome
| Grade III Glioma
|
Grade IV Glioma
|
|||||
|---|---|---|---|---|---|---|
| Outcome | TMZ | Other | Total | TMZ | Other | Total |
| Progression-free survivala | ||||||
| No. patients (no. censored) | 56 (10) | 103 (19) | 159 (29) | 146 (24) | 291 (35) | 437 (59) |
| % PFS (95% CI)b | ||||||
| 9 weeks | 76 (63–86) | 40 (30–50) | 53 (45–61) | 65 (56–72) | 34 (28–40) | 44 (40–49) |
| 18 weeks | 52 (38–65) | 22 (14–31) | 33 (25–40) | 40 (31–48) | 17 (13–22) | 25 (20–29) |
| 26 weeks | 47 (33–59) | 17 (10–26) | 28 (21–35) | 28 (21–36) | 9 (6–13) | 16 (12–20) |
| Median PFS (95% CI), weeks | 24 (16–29) | 8 (7–9) | 11 (9–13) | 15 (11–17) | 7 (7–8) | 8 (8–9) |
| Survivala | ||||||
| No. patients (no. censored) | 56 (11) | 103 (19) | 159 (30) | 146 (10) | 291 (12) | 437 (22) |
| % Surviving (95% CI)b | ||||||
| 26 weeks | 82 (69–90) | 57 (47–66) | 66 (58–73) | 69 (61–76) | 48 (43–54) | 55 (51–60) |
| 52 weeks | 51 (37–63) | 40 (30–49) | 44 (36–51) | 37 (29–45) | 19 (14–23) | 25 (21–29) |
| 78 weeks | 27 (16–39) | 25 (17–34) | 27 (20–34) | 21 (15–28) | 8 (5–12) | 13 (10–16) |
| Median survival (95% CI), weeks | 52 (37–60) | 36 (24–49) | 39 (32–54) | 40 (33–47) | 26 (23–29) | 30 (27–33) |
Abbreviations: TMZ, temozolomide; PFS: progression-free survival; 95% CI, 95% confidence interval.
a
Estimated from Kaplan-Meier curves.
b
From time of protocol registration or first subsequent postoperative treatment.